Creo Medical Group PLC (LON:CREO - Get Free Report) dropped 1.6% during mid-day trading on Monday . The stock traded as low as GBX 13.75 ($0.19) and last traded at GBX 14.25 ($0.20). Approximately 429,776 shares changed hands during trading, a decline of 69% from the average daily volume of 1,374,790 shares. The stock had previously closed at GBX 14.48 ($0.20).
Creo Medical Group Stock Performance
The company has a 50 day simple moving average of GBX 12.35 and a 200 day simple moving average of GBX 14.62. The stock has a market cap of £55.12 million, a price-to-earnings ratio of -2.16 and a beta of 0.86. The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96.
Creo Medical Group (LON:CREO - Get Free Report) last posted its quarterly earnings data on Monday, May 19th. The company reported GBX (8) (($0.11)) EPS for the quarter. Creo Medical Group had a negative net margin of 73.93% and a negative return on equity of 41.79%. As a group, equities research analysts forecast that Creo Medical Group PLC will post -10.0800005 EPS for the current year.
Insider Buying and Selling
In other Creo Medical Group news, insider Kevin Crofton acquired 701,750 shares of the business's stock in a transaction on Friday, May 30th. The shares were acquired at an average price of GBX 16 ($0.22) per share, with a total value of £112,280 ($154,082.61). 22.43% of the stock is currently owned by corporate insiders.
About Creo Medical Group
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Recommended Stories
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
